Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes

Heart

Volumn 100, Issue 22, 2014, Pages 1762-1769

  Varenhorst, Christoph ^a,b   Alström, Ulrica ^a   Braun, Oscar Ö ^c   Storey, Robert F ^d   Mahaffey, Kenneth W ^e   Bertilsson, Maria ^b   Cannon, Christopher P ^f   Scirica, Benjamin M ^f   Himmelmann, Anders ^g   James, Stefan K ^a,b   Wallentin, Lars ^a,b   Held, Claes ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PROTON PUMP INHIBITOR; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOODSTREAM INFECTION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG FATALITY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; INFECTION; ISCHEMIC HEART DISEASE; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN DEATH; SUICIDE; SURGICAL INFECTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT DURATION; URINARY TRACT INFECTION; AGE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL; TIME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGE FACTORS; AGED; CAUSE OF DEATH; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TICLOPIDINE; TIME FACTORS;

EID: 84908253107     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305619     Document Type: Article

References (23)

1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
2. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85.
3. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56:1456-62.
4. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84.
5. Varenhorst C, Alström U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60:1623-30.
6. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605.
7. Garfinkle M, Lawler PR, Filion KB, et al. Red blood cell transfusion and mortality among patients hospitalized for acute coronary syndromes: a systematic review. Int J Cardiol 2013;164:151-7.
8. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44.
9. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47.
10. Van Giezen JJJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17:164-72.
11. Ohman J, Kudira R, Albinsson S, et al. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012;418:754-8.
12. Alexopoulos D, Moulias A, Koutsogiannis N, et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv 2013;6:277-83.
13. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27:2400-5.
14. Hale SL, Kloner RA. Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J Cardiovasc Pharmacol Ther 2010;15:60-7.
15. Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010;104:609-17.
16. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri. J Am Coll Cardiol 2007;50:1844-51.
17. Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr. J Am Coll Cardiol 2011;57:1908-16.
18. Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 15 Oct 2013 [Epub ahead of print]
19. Blasco-Colmenares E, Perl TM, Guallar E, et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009;169:788-96.
20. Steinhubl SR, Badimon JJ, Bhatt DL, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007;12:113-22. http://www.ncbi.nlm.nih.gov/pubmed/17615799 (accessed 13 Nov2013)
21. Ge H, Zhou Y, Liu X, et al. Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty. Angiology 2012;63:62-6.
22. Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010;104:1193-200.
23. Rahman M, Gustafsson D, Wang Y, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets 2014;25:257-63.